Standard three-drug H. pylori therapy beats newer four-drug regimens in Latin America study

Clinical trials in Europe and Asia were thought to have pinpointed the best treatment regimen to eradicate the H. pylori bug, an important cause of peptic ulcers and gastric cancer. New results from a large study in Latin America turn those findings on their head, suggesting different populations need different therapies.

Read the whole article on Science Daily

More from Science Daily